Stanford stem cell biologists have found a way to block a signal that causes growth of breast cancer cells, opening potential for new treatments.
In breast and lung cancer patients with metastatic disease, seeds of metastasis were often planted before the primary tumor was diagnosed, a study finds.
The experts on Stanford Medicine's molecular tumor board brainstorm new ways to attack individual patients' tumors at the genetic level.
In this episode of "The Future of Everything," host Russ Altman and guest Ross Shachter discuss how AI can help radiologists with diagnosis accuracy.
Surgeon Irene Wapnir and her colleagues developed a new technique for creating biological breast implants for women who have undergone a mastectomy.
Stanford researchers develop a machine-learning computer model for mammography assessment in hopes of aiding radiologists’ clinical decisions.
Stanford researchers make progress in predicting which patients will suffer heart problems from chemotherapy, and may have found a drug to mitigate them.
Molecular data identifies breast cancer subgroups likely to recur decades after successful treatment, predicts probable timing and location of metastases.
Stanford researchers have learned that cancer cells can batter their way into new territory, rather than relying on dissolving chemicals.
Mapping the geography of the immune response in triple negative breast cancers predicts patient survival and sheds light onto new aspects of tumor biology.
Women with breast cancer are increasingly receiving multigene genetic testing rather than just screening for the BRCA mutations, new research suggests.
Breast cancer in men and women differ in levels of cancer-associated gene expression and the relative risk of recurrence after initially successful treatment. Some men have a higher risk than women, whereas others have a much lower risk.
Breast underdevelopment at puberty is associated with a shortage of several hormones produced by the pituitary gland, a condition called combined pituitary hormone deficiency (CPHD). …
Breast cancer patients are often faced with a difficult decision at the end of their primary treatment: Should they get systemic adjuvant therapy, such as …
As the death last year of neurosurgeon Paul Kalanithi, MD, reminded us all, successful physicians aren't protected from the onslaught of medical maladies that can …
My close childhood friend Kelly died from breast cancer when she was only 32 years old. This inspired me to choose a research position at …
